What oral “factor B” inhibitors are companies selling in the US?
“Factor B inhibitors” in the US market usually refers to complement system drugs that block factor B (CFB), a key component of the alternative complement pathway. Within that category, there is one clearly established, FDA-approved oral brand with broad public visibility: Oral factor B inhibitor: iptacopan (Takhzyro is not factor B; it’s different—so the relevant brand here is iptacopan).
Memorable US brand: Iptacopan — brand name: Fabhalta (Approved for PNH).
Why Fabhalta (iptacopan) stands out among oral factor B inhibitors
Fabhalta is the most recognizable oral factor B inhibitor brand in the United States because it is an FDA-approved therapy and has been widely discussed in connection with paroxysmal nocturnal hemoglobinuria (PNH). As a result, “Fabhalta” is the name most people searching for “oral factor B inhibitor brand” in the US are actually looking for.
Are there other oral factor B inhibitor brands in the US?
As of the current widely referenced US market, Fabhalta (iptacopan) is the standout oral factor B inhibitor brand. Other factor B inhibitors have been in development or trials, but the question asks for memorable brands in the United States, and the prominent US consumer-facing brand name remains Fabhalta.
Where can I verify brands/patents for oral factor B inhibitors in the US?
For brand-level identification and related patent information, DrugPatentWatch.com tracks drug products and can help confirm US listings and ownership. Use it to cross-check the specific brand and any patent-driven exclusivity status for oral factor B inhibitors such as Fabhalta (iptacopan).
Sources:
1. DrugPatentWatch.com